Unresolved questions regarding the promise of the TPEx regimen – Authors' reply

Joël Guigay; Anne Auperin; Aldéric Fraslin; Ulrich Keilholz; Jean Bourhis; Ricard Mesia

doi:10.1016/S1470-2045(21)00293-X

Unresolved questions regarding the promise of the TPEx regimen – Authors' reply

Joël Guigay, Anne Auperin, Aldéric Fraslin, Ulrich Keilholz, Jean Bourhis, Ricard Mesia

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

3 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	e228-e229
journal	The Lancet Oncology
Volume	22
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/S1470-2045(21)00293-X
état	Publié - 1 juin 2021

Accès au document

10.1016/S1470-2045(21)00293-X

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{cf7a7231c7c043729d6888acf8bc9571,

title = "Unresolved questions regarding the promise of the TPEx regimen – Authors' reply",

author = "Jo{\"e}l Guigay and Anne Auperin and Ald{\'e}ric Fraslin and Ulrich Keilholz and Jean Bourhis and Ricard Mesia",

note = "Funding Information: JG has received research grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS), Chugai, GlaxoSmithKline, Merck Serono, and Sanofi; and has been an advisory board member for AstraZeneca, BMS, Innate Pharma, and Merck, all outside the submitted work. AA has received grant support, paid to her institution, from the Groupe d'Oncologie Radiotherapie T{\^e}te et Cou (GORTEC; French Radiation and Oncology Group for Head and Neck) for the original study and has received grant support, paid to her institution, from F Hoffmann–La Roche, outside the submitted work. AF has received grant support, paid to his institution, from the GORTEC for the original study. UK has received grants and personal fees from Merck, outside the submitted work. JB participated in advisory boards for Merck Sharp & Dohme, BMS, Debiopharm, Merck, and AstraZeneca, outside the submitted work. RM has received research grants from Merck Serono and has been an advisory board member for AstraZeneca, BMS, Rakuten, Merck Serono, Merck Sharp & Dohme, Nanobiotics, Bayer, and Roche, all outside the submitted work.",

year = "2021",

month = jun,

day = "1",

doi = "10.1016/S1470-2045(21)00293-X",

language = "English",

volume = "22",

pages = "e228--e229",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "6",

}

TY - JOUR

T1 - Unresolved questions regarding the promise of the TPEx regimen – Authors' reply

AU - Guigay, Joël

AU - Auperin, Anne

AU - Fraslin, Aldéric

AU - Keilholz, Ulrich

AU - Bourhis, Jean

AU - Mesia, Ricard

N1 - Funding Information: JG has received research grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS), Chugai, GlaxoSmithKline, Merck Serono, and Sanofi; and has been an advisory board member for AstraZeneca, BMS, Innate Pharma, and Merck, all outside the submitted work. AA has received grant support, paid to her institution, from the Groupe d'Oncologie Radiotherapie Tête et Cou (GORTEC; French Radiation and Oncology Group for Head and Neck) for the original study and has received grant support, paid to her institution, from F Hoffmann–La Roche, outside the submitted work. AF has received grant support, paid to his institution, from the GORTEC for the original study. UK has received grants and personal fees from Merck, outside the submitted work. JB participated in advisory boards for Merck Sharp & Dohme, BMS, Debiopharm, Merck, and AstraZeneca, outside the submitted work. RM has received research grants from Merck Serono and has been an advisory board member for AstraZeneca, BMS, Rakuten, Merck Serono, Merck Sharp & Dohme, Nanobiotics, Bayer, and Roche, all outside the submitted work.

PY - 2021/6/1

Y1 - 2021/6/1

UR - http://www.scopus.com/inward/record.url?scp=85107132945&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(21)00293-X

DO - 10.1016/S1470-2045(21)00293-X

M3 - Letter

C2 - 34087138

AN - SCOPUS:85107132945

SN - 1470-2045

VL - 22

SP - e228-e229

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 6

ER -